WHO’s Priority Pathogens List: How It Guides the Fight Against Antibiotic Resistance

Antibiotic resistance is often described as a future threat. It is already a present clinical problem: infections become harder to treat, hospital stays can lengthen, procedures become riskier, and the chance of death rises when effective medicines are limited.

The World Health Organization updated its Bacterial Priority Pathogens List in 2024 to help governments, researchers, and funders decide where attention is most urgent. The list covers 24 pathogens across 15 families and organizes them into critical, high, and medium priority groups.

What “priority” means

The categories consider several factors, including disease burden, trends in resistance, transmissibility, preventability, available treatments, and the state of the research pipeline. A critical-priority organism is not necessarily the organism most likely to harm every individual patient. It is a signal that the combination of resistance and unmet public-health need demands exceptional attention.

The list is global, while local treatment decisions must rely on clinical context and regional surveillance. Resistance patterns can differ between countries, hospitals, communities, and even wards. Clinicians therefore need local antibiograms and laboratory results in addition to international guidance.

Why the 2024 update matters

Pathogens and treatment landscapes change. Resistance mechanisms spread, new evidence becomes available, and some drug-development pipelines improve while others remain thin. Updating the list makes prioritization responsive rather than permanent.

Critical priorities include difficult Gram-negative organisms where resistance can leave very few treatment options. High and medium groups include other bacteria that create substantial healthcare and community burdens. The categories are intended to guide investment, not stigmatize patients or imply that lower-ranked pathogens are unimportant.

New antibiotics are necessary but insufficient

Drug development is essential, especially where existing antibiotics are failing. But every new antibiotic can eventually face resistance. A strategy based only on discovering replacements will repeat the same cycle if medicines are then used poorly or infection prevention is neglected.

Research also needs rapid diagnostics, vaccines, alternative treatments, and evidence on how to use existing drugs more precisely. Diagnostics can reduce unnecessary broad-spectrum treatment by identifying whether an infection is bacterial and which medicine is likely to work.

Stewardship is not simply “use fewer antibiotics”

Antimicrobial stewardship aims to provide the right drug, dose, route, and duration when treatment is needed—and avoid antibiotics when they are not. Delaying effective treatment for a serious bacterial infection is harmful. Prescribing antibiotics for a viral illness is also harmful because it provides no benefit and adds selective pressure.

Good stewardship requires trained clinicians, microbiology capacity, reliable supplies, prescribing feedback, and access to appropriate medicines. It cannot be reduced to blaming individual patients or prescribers.

Prevention reduces the need for treatment

Hand hygiene, vaccination, clean water, sanitation, safe food systems, infection-control practices, and protection of healthcare workers all reduce infections and therefore antibiotic use. Surveillance links these measures by showing where resistance is emerging and whether interventions work.

The US Centers for Disease Control and Prevention notes that antimicrobial resistance contributed to a major global burden in 2019, including at least 1.27 million deaths directly attributable to resistant infections. Such estimates also carry uncertainty, particularly where laboratory and mortality data are limited, which makes stronger surveillance part of the solution.

What this means

The WHO list is best read as a portfolio guide. Critical pathogens need urgent research, but high- and medium-priority organisms still require surveillance and prevention. Governments need laboratory networks and stewardship; researchers need incentives aligned with unmet need; manufacturers need responsible access plans; health systems need reliable infection control.

Antimicrobial resistance crosses hospitals, communities, agriculture, food, animals, and the environment. No single discovery will solve it. The priority list helps direct limited resources, while durable progress depends on combining innovation with prevention and careful use of the treatments already available.